Parikh S - Search Results

1

Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.

Jabbour SA, Whaley JM, Tirmenstein M, Poucher SM, Reilly TP, Boulton DW, Saye J, List JF, Parikh S. Jabbour SA, et al. Among authors: parikh s. Postgrad Med. 2012 Jul;124(4):62-73. doi: 10.3810/pgm.2012.07.2569. Postgrad Med. 2012. PMID: 22913895 Review.

2

Effects of dapagliflozin on cardiovascular risk factors.

Ptaszynska A, Hardy E, Johnsson E, Parikh S, List J. Ptaszynska A, et al. Among authors: parikh s. Postgrad Med. 2013 May;125(3):181-9. doi: 10.3810/pgm.2013.05.2667. Postgrad Med. 2013. PMID: 23748519 Review.

3

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin.

Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Johnsson KM, et al. J Diabetes Complications. 2013 Sep-Oct;27(5):479-84. doi: 10.1016/j.jdiacomp.2013.04.012. Epub 2013 Jun 24. J Diabetes Complications. 2013. PMID: 23806570

4

Urinary tract infections in patients with diabetes treated with dapagliflozin.

Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Johnsson KM, et al. J Diabetes Complications. 2013 Sep-Oct;27(5):473-8. doi: 10.1016/j.jdiacomp.2013.05.004. Epub 2013 Jul 10. J Diabetes Complications. 2013. PMID: 23849632

5

Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.

Jabbour SA, Hardy E, Sugg J, Parikh S; Study 10 Group. Jabbour SA, et al. Among authors: parikh s. Diabetes Care. 2014;37(3):740-50. doi: 10.2337/dc13-0467. Epub 2013 Oct 21. Diabetes Care. 2014. PMID: 24144654 Clinical Trial.

6

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus.

Whaley JM, Tirmenstein M, Reilly TP, Poucher SM, Saye J, Parikh S, List JF. Whaley JM, et al. Among authors: parikh s. Diabetes Metab Syndr Obes. 2012;5:135-48. doi: 10.2147/DMSO.S22503. Epub 2012 Jul 23. Diabetes Metab Syndr Obes. 2012. PMID: 22923998 Free PMC article.

7

Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.

Ptaszynska A, Johnsson KM, Parikh SJ, de Bruin TW, Apanovitch AM, List JF. Ptaszynska A, et al. Drug Saf. 2014 Oct;37(10):815-29. doi: 10.1007/s40264-014-0213-4. Drug Saf. 2014. PMID: 25096959

8

Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time.

Parikh S, Wilding J, Jabbour S, Hardy E. Parikh S, et al. Int J Clin Pract. 2015 Feb;69(2):186-98. doi: 10.1111/ijcp.12531. Epub 2014 Nov 28. Int J Clin Pract. 2015. PMID: 25438821

9

Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria.

Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Geerlings S, et al. Among authors: parikh s. Diabetes Res Clin Pract. 2014 Mar;103(3):373-81. doi: 10.1016/j.diabres.2013.12.052. Epub 2014 Jan 8. Diabetes Res Clin Pract. 2014. PMID: 24529566 Free article. Review.

10

Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.

Johnsson K, Johnsson E, Mansfield TA, Yavin Y, Ptaszynska A, Parikh SJ. Johnsson K, et al. Postgrad Med. 2016 May;128(4):346-55. doi: 10.1080/00325481.2016.1153941. Epub 2016 Mar 2. Postgrad Med. 2016. PMID: 26878357

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,175 results

Search Page

Filters